MiNK Therapeutics, Inc. Stock Split Ratio
MiNK Therapeutics, Inc. (INKT) had Stock Split Ratio of 10.00% as of 2025-01-28, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-13
- 2025-01-28: Stockholders' Equity Note, Stock Split, Conversion Ratio 10.00%.
- 2025-01-17: Stockholders' Equity Note, Stock Split, Conversion Ratio 10.00%.
- 2021-09-30: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 278.30%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|---|
| 2025-01-28 | 10.00% 10-Q · filed 2026-08-13 | |
| 2025-01-17 | 10.00% 10-K · filed 2026-03-31 | |
| 2021-09-30 | 278.30% 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |